Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
A2 Biotherapeutics, Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, indicating separate examination contexts across the portfolio.
CANELLA, KAREN A is the busiest examiner, with 1 pending matter. Counsel should coordinate the broader biotechnology strategy while managing claim scope, evidence, and response practice separately for each pending record.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANELLA, KAREN A | 1 | 62.3% | +32.8% |
| SPENCE, JENNIFER SUZANNE | 1 | 66.9% | +46.0% |
| TIWARI, VYOMA SHUBHAM | 1 | 32.1% | +47.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18062873 | COMPOSITIONS AND METHODS FOR TREATING MESOTHELIN POSITIVE CANCERS | SPENCE, JENNIFER SUZANNE | 86d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18062873 | COMPOSITIONS AND METHODS FOR TREATING MESOTHELIN POSITIVE CANCERS | SPENCE, JENNIFER SUZANNE | 86d overdue |
| 18165623 | COMPOSITIONS AND METHODS FOR TREATING EGFR POSITIVE CANCERS | CANELLA, KAREN A | 46d overdue |
| 17480501 | CONTROLLING PROXIMITY OF IMMUNE CELL RECEPTORS | TIWARI, VYOMA SHUBHAM | 22d |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1633 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18165623 | COMPOSITIONS AND METHODS FOR TREATING EGFR POSITIVE CANCERS | CANELLA, KAREN A | 1643 | §102§103§112DP | Final Rejection | 46d overdue | Pending | Feb 07, 2023 |
| 18062873 | COMPOSITIONS AND METHODS FOR TREATING MESOTHELIN POSITIVE CANCERS | SPENCE, JENNIFER SUZANNE | 1633 | §103§112Other | Final Rejection | 86d overdue | Pending | Dec 07, 2022 |
| 17480501 | CONTROLLING PROXIMITY OF IMMUNE CELL RECEPTORS | TIWARI, VYOMA SHUBHAM | 1634 | §112 | Non-Final OA | 22d | Pending | Sep 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialA2 Biotherapeutics, Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Karen A Canella has the most, with 1 of A2 Biotherapeutics, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
